RxDoctor Payments Data

Linda Mercado

Physician Assistant · Hidalgo, TXNPI 1033739883

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Gilead accounts for 65.9% of it on its own, with 11 other manufacturers making up the rest. Among physician assistant clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$36,862in general payments, 2019–2025

Across 340 payments — averaging $108.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$24K
  • Viiv Healthcare Company$11K
  • Johnson & Johnson$512
  • Theratechnologies Inc.$392
  • Janssen Products, LP$299
  • Merck$157
  • plus $384 from 6 others
$42,296in research payments, 2019–2025

Across 18 payments — averaging $2349.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$25K
  • Gilead$18K

What the payments were for

  • Consulting fees$3,92011%
  • Speaking & faculty fees$17,42847%
  • Travel & lodging$7,80021%
  • Food & beverage$7,35820%
  • Education$3561%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,862 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala146$561,036
RukobiaFostemsavir Tromethamine36$310,133
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf65$301,199
JulucaDolutegravir/Rilpivirine76$261,793
DovatoDolutegravir Sodium/Lamivudine85$235,818
Egrifta SvTesamorelin Acetate28$197,777
CabenuvaCabotegravir/Rilpivirine27$169,305
TivicayDolutegravir Sodium53$113,273
PrezcobixDarunavir/Cobicistat24$56,227
TriumeqAbacavir/Dolutegravir/Lamivudi13$48,836
DescovyEmtricitabine/Tenofov Alafenam16$32,006
ValacyclovirValacyclovir Hcl33$1,436
Ciclopirox16$709
Fluconazole13$336
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim14$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyRukobia, Juluca, Dovato, Cabenuva, Tivicay$10,831$1,139,156290 claims
GileadBiktarvy, Descovy$24,286$593,041162 claims
Janssen Products, LPSymtuza$299$301,19965 claims
Theratechnologies Inc.Egrifta Sv$392$197,77728 claims
Johnson & JohnsonPrezcobix$512$56,22724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Hidalgo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →